NICE hears Bayer's Nexavar appeal
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, on Friday heard Bayer's appeal against the institute's guidance that rejected Nexavar (sorafenib) for advanced hepatocellular carcinoma for use on the NHS.